This is a promotional website fully funded and created by SERB Pharmaceuticals for UK Healthcare Professionals only.
If you are a member of public please click here

Report Adverse Event Here | Prescribing Information | Summary of Product Characteristics

Benefit of Injectable treatment

MYXOEDEMA COMA & HYPOTHYROIDISM
HIGH PREVALENCE IN WOMEN1

HYPOTHYROIDISM

  • Prevalence of clinical primary hypothyroidism: between 0.2-5.3% in Europe2
  • Frequent in women around the age of 603
  • Levothyroxine is offered as first-line treatment for adults, children & young people (NICE* 2019)4
  • Levothyroxine is recommended to be considered as routine care for patients (ATA* 2014)5

MYXOEDEMA COMA

  • Extreme form of hypothyroidism6
  • 80% of cases occur in women6
  • 90% of cases occur in winter6
  • High mortality rate between 30%-60%6
Intravenous levothyroxine
is part of the treatment for
hypothyroidism, in addition to
other medicines and supportive
care. (ATA* 2015)7

*American Thyroid Association (ATA); National Institute for Health and Clinical Excellence (NICE)

References:
  1. Wartofsky L. Myxedema coma. Endocrinol Metab Clin N Am. 2006. 35: 687-698
  2. Chaker L. et al. Hypothyroidism. Lancet. 2017. 390: 1550-1562
  3. Hypothyroidism: patient perception, clinical & TSH are essential. HAS (French National Authority for Health). 2019
  4. NICE guideline. Thyroid disease: assessment and management. November 2019
  5. Jonklaas J. et al. Guidelines for the treatment of Hypothyroidism. American Thyroid Association. 2014. 24 (12): 1670-1751
  6. Wall C. Myxedema Coma: Diagnosis and Treatment. Am Fam Physician. 2012. 62 (11): 2485-2490
  7. Vellanki P. American Thyroid Association Guideline. May 2015